Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Aberdeen Group plc

Aberdeen Group plc lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 18.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,597 shares of the company’s stock after purchasing an additional 9,728 shares during the period. Aberdeen Group plc owned about 0.15% of Tarsus Pharmaceuticals worth $2,495,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. Valmark Advisers Inc. acquired a new stake in Tarsus Pharmaceuticals in the first quarter valued at approximately $283,000. Amalgamated Bank grew its stake in Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after acquiring an additional 295 shares during the period. Arizona State Retirement System grew its stake in Tarsus Pharmaceuticals by 6.1% in the 1st quarter. Arizona State Retirement System now owns 8,182 shares of the company’s stock valued at $420,000 after acquiring an additional 470 shares during the period. Victory Capital Management Inc. increased its holdings in Tarsus Pharmaceuticals by 999.5% in the 1st quarter. Victory Capital Management Inc. now owns 44,320 shares of the company’s stock worth $2,277,000 after acquiring an additional 40,289 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Tarsus Pharmaceuticals during the first quarter worth $1,818,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $72.93 on Friday. The company has a market cap of $3.08 billion, a P/E ratio of -31.30 and a beta of 0.81. Tarsus Pharmaceuticals, Inc. has a twelve month low of $35.84 and a twelve month high of $76.81. The company’s 50-day moving average price is $58.73 and its 200-day moving average price is $49.01. The company has a current ratio of 5.26, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The business had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the transaction, the chief executive officer owned 812,106 shares in the company, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William J. Phd Link sold 27,116 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. The trade was a 15.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,116 shares of company stock valued at $2,177,832. Insiders own 8.97% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.